iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

NCT03608631 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

KRAS NP_004976.2:p.G12D
Metastatic Pancreatic Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8

Interventions

DRUG: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA

Sponsor

M.D. Anderson Cancer Center